Skip to main content

Latest news

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

TNF-guided infliximab dose escalation does not improve RA remission rates

IV drip 2

Adjustment of infliximab dosing based on serum tumor necrosis factor-α levels has no impact on rates of remission and sustained treatment discontinuation among patients with rheumatoid arthritis, indicate results from the RRRR trial.

Interleukin inhibitors linked to elevated infection, cancer risk


Results of a meta-analysis suggest that treatment with interleukin inhibitors may be associated with an increased risk for infections and cancer among people with rheumatic diseases.

Etanercept not linked to uveitis risk in real-world JIA study

Child's eye exam (symbolic image with model)

An analysis of two UK juvenile idiopathic arthritis registries suggests no significant difference in uveitis risk among patients treated with the TNF inhibitor etanercept relative to methotrexate.

Differential DNA methylation may help identify likely methotrexate responders


Changes in DNA methylation following initiation of methotrexate appear to correlate with response to the drug in patients with rheumatoid arthritis, study findings indicate.

Elevated IFN-α linked to relapse risk in SLE

Blood sample

A quarter of patients in remission for systemic lupus erythematosus have elevated serum interferon-α levels and may be at increased risk for relapse, French researchers report.

Continuous NSAID use linked to hypertension risk in ankylosing spondylitis

Blood pressure measurement

Individuals with ankylosing spondylitis who continually use NSAIDs have an increased risk for hypertension relative to those who use the drugs less frequently, study findings indicate.

Multiple modifiable risk factors impact post hip replacement dislocation risk

Hip replacement

Dislocation risk following total hip replacement is declining with time and is associated with a number of surgical, hospital, and patient-related factors that are generally modifiable, UK researchers report.

Global RA burden ‘significant, yet under-recognized’

Stethoscope and globe

Almost 20 million people worldwide were living with rheumatoid arthritis in 2017, with over a million new cases diagnosed each year, according to estimates from the Global Burden of Diseases, Injuries, and Risk Factors Study.

Preliminary trial results support further investigation of low-dose IL-2 therapy for SLE

Doctor and needle

The low-dose recombinant IL-2 therapy aldesleukin has a favorable safety profile and may restore regulatory T-cell homeostasis in people with systemic lupus erythematosus, suggest findings from a proof-of-concept phase I/IIa clinical trial.

Alcohol consumption linked to axSpA progression

Alcoholic drinks

Alcohol consumption may be a modifiable risk factor for spinal structural damage among patients with axial spondyloarthritis, researchers report.

Meta-analysis questions use of osteoporosis treatments to reduce mortality risk

Osteoporosis bone

Findings from a meta-analysis published in JAMA Internal Medicine indicate that drug treatments for osteoporosis, particularly bisphosphonates, are not associated with a significant reduction in overall mortality risk.

Support for switching between upadacitinib and adalimumab in RA patients

Rheumatoid arthritis medication

48-week results from the SELECT-COMPARE study indicate that upadacitinib has sustained efficacy in patients with rheumatoid arthritis, and that individuals with an inadequate response to upadacitinib or adalimumab may benefit from switching to the alternate therapy.

NSAIDs contribute ‘substantially’ to increased CVD risk in osteoarthritis

New Content Item

People with osteoarthritis have a significantly higher risk for developing cardiovascular disease than those without, and the use of nonsteroidal anti-inflammatory drugs mediates a considerable proportion of this association, researchers report.

Machine learning shows promise for predicting TNF inhibitor response

Machine learning

A machine-learning model may help to predict which rheumatoid arthritis patients are likely to respond to treatment with TNF inhibitors, researchers report.

FINCH 2: Further evidence for filgotinib as a treatment option for RA


Rheumatoid arthritis patients with an inadequate response or intolerance to biologic DMARDs who are treated with the selective JAK1 inhibitor filgotinib are more likely to achieve a clinical response than those given placebo, phase III trial results suggest.

Partial knee replacement recommended for medial compartment osteoarthritis

Knee arthroplasty concept image (symbolic image with model)

Partial knee replacement is more cost-effective than total knee replacement over 5 years for patients with late-stage isolated medial compartment osteoarthritis of the knee, show results of the TOPKAT trial published in The Lancet.

Latest headlines

18-11-2019 | Systemic lupus erythematosus | ACR/ARP 2019 | Article

No benefit of add-on fenebrutinib for patients with SLE

Addition of the Bruton’s tyrosine kinase inhibitor fenebrutinib to standard care does not improve outcomes for patients with systemic lupus erythematosus, suggest findings from a phase II trial.

15-11-2019 | Systemic lupus erythematosus | ACR/ARP 2019 | News

Further investigation of telitacicept may be warranted for SLE

Telitacicept, a recombinant fusion protein targeting B-lymphocyte stimulator and the APRIL proliferation-inducing ligand, has shown potential for the treatment of systemic lupus erythematosus in a phase IIb trial conducted in China.

14-11-2019 | Psoriatic arthritis | ACR/ARP 2019 | News

Sustained benefits of ixekizumab over adalimumab in PsA

Follow-up results from the SPIRIT-H2H trial indicate that ixekizumab continues to improve joint and skin symptoms relative to adalimumab after 1 year of treatment among patients with psoriatic arthritis.

In depth

13-09-2019 | Axial spondyloarthritis | Feature | Article

A closer look at the US guidelines for managing axSpA

Michael Ward talks about what’s new in the updated US guidelines for the management of ankylosing spondylitis and nonradiographic axial spondyloarthritis.

13-09-2019 | Ankylosing spondylitis | Feature | Article

At a glance: Phase III trials of IL-17A inhibitors in ankylosing spondylitis

A quick-reference guide to the phase III trials of IL-17A inhibitors for the treatment of ankylosing spondylitis.

21-08-2019 | Tofacitinib | Feature | Article

Tofacitinib black box warning: A cause for concern?

Roy Fleischmann puts the new FDA boxed warning of increased pulmonary embolism and death risk with tofacitinib into context for rheumatologists and their patients.

Image Credits